S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
Log in

NYSE:IVAInventiva Stock Price, Forecast & News

$10.67
+0.17 (+1.62 %)
(As of 08/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$10.50
Now: $10.67
$11.26
50-Day Range N/A
52-Week Range
$9.01
Now: $10.67
$15.95
Volume104,022 shs
Average Volume190,448 shs
Market Capitalization$407.23 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Inventiva S.A., a biopharmaceutical company, develops drugs for the treatment of fibrotic, cancer, and orphan diseases. Its lead product candidate is Lanifibranor that is in Phase IIb clinical trial to treat nonalcoholic steatohepatitis and systemic sclerosis. The company also develops Odiparcil, which is in Phase IIa clinical trial primarily for the treatment of mucopolysaccharidosis type VI disease; YAP-TEAD that is in preclinical stage to treat malignant mesothelioma and lung cancer; NSD2 for the treatment of multiple myeloma; and EPICURE for immuno-oncology treatment. It has partnership collaborations with the Institut Curie in the field of oncology; AbbVie for developing ROR? project that is used for the treatment of autoimmune diseases, as well as other projects relating to fibrosis; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.00 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone33 3 80 44 75 00

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees84
Market Cap$407.23 million
Next Earnings DateN/A
OptionableNot Optionable
$10.67
+0.17 (+1.62 %)
(As of 08/5/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IVA News and Ratings via Email

Sign-up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Inventiva (NYSE:IVA) Frequently Asked Questions

Has Inventiva been receiving favorable news coverage?

Media coverage about IVA stock has trended neutral on Wednesday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Inventiva earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
View the latest news about Inventiva
.

Who are some of Inventiva's key competitors?

Who are Inventiva's key executives?

Inventiva's management team includes the following people:
  • Mr. Frédéric Cren, Co-Founder, CEO & Chairman (Age 54)
  • Dr. Pierre Broqua, Co-Founder, Chief Scientific Officer & Deputy CEO (Age 58)
  • Mr. Jean Volatier, Chief Financial Officer (Age 56)
  • Mr. Nicolas Gueugnon, Legal Director
  • Ms. Nathalie Harroy, Head of HR

When did Inventiva IPO?

(IVA) raised $103 million in an initial public offering on Friday, July 10th 2020. The company issued 7,500,000 shares at $13.68 per share. Jefferies, Stifel and Guggenheim Securities acted as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers.

What is Inventiva's stock symbol?

Inventiva trades on the New York Stock Exchange (NYSE) under the ticker symbol "IVA."

When does Inventiva's quiet period expire?

Inventiva's quiet period expires on Wednesday, August 19th. Inventiva had issued 7,478,261 shares in its public offering on July 10th. The total size of the offering was $107,686,958 based on an initial share price of $14.40. During Inventiva's quiet period, insiders and any underwriters that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Inventiva?

Shares of IVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Inventiva's stock price today?

One share of IVA stock can currently be purchased for approximately $10.67.

How big of a company is Inventiva?

Inventiva has a market capitalization of $407.23 million. Inventiva employs 84 workers across the globe.

What is Inventiva's official website?

The official website for Inventiva is www.inventivapharma.com.

How can I contact Inventiva?

The company can be reached via phone at 33 3 80 44 75 00.

This page was last updated on 8/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.